The World According to Boyar cover image

From Book Value To Brand Value. Bill Nygren On Why Modern Investing Requires Seeing Beyond The Balance Sheet

The World According to Boyar

00:00

Valuing Pharma: Merck and Patent Risk

Bill explains asset-by-asset DCFs for finite-life assets, Merck's Keytruda runoff, and how pipeline and extensions factor into valuation.

Play episode from 37:59
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app